Department of laboratory medicine, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, People's Republic of China.
IUBMB Life. 2012 May;64(5):423-31. doi: 10.1002/iub.1016. Epub 2012 Mar 31.
Tumstatin is a candidate tumor suppressor that plays an important role in tumor growth and angiogenesis. The purpose of this study was to evaluate the correlation between tumstatin-mRNA expression and the clinicopathologic characteristics, tumor angiogenesis, outcome of patients with non-small cell lung cancer (NSCLC). Specimens from 68 patients with NSCLC were recruited in this study. Tumstatin-mRNA expression and protein level in tumor tissues were quantified respectively by quantitative RT-PCR and ELISA. Microvessel density (MVD) was determined by CD34 immunostaining. The correlation of tumstatin-mRNA expression levels with clinicopathologic variables, tumor angiogenesis, and prognosis was analyzed. Tumstatin-mRNA expression levels were decreased in tumor. Tumstatin-mRNA expression level was significantly correlated with its protein level in tumor (r = 0.562; P = 0.001). Tumstatin-mRNA expression levels in poorly differentiated tumor tissues were significantly lower than in well-differentiated tumor tissues (P < 0.004). Furthermore, tumor tumstatin-mRNA expression were also significantly related to tumor pathologic stage (P = 0.032) and MVD (r = -0.77, P < 0.0001). Overall survival (OS) and disease-free survival (DFS) analysis indicated that NSCLC patients with low tumstatin-mRNA expression had poorer OS and DFS than those with high expression (P = 0.015 and 0.037; respectively). Multivariable Cox regression analysis revealed that the tumstatin-mRNA expression could be an independent prognostic indicators in both DFS and OS. Tumstatin-mRNA expression levels are down-regulated in NSCLC tissues. Tumstatin-mRNA expression level correlates with prognosis, which suggests that tumstatin-mRNA is a new potential independent marker of favorable prognosis in NSCLC.
肿瘤抑素是一种候选肿瘤抑制因子，在肿瘤生长和血管生成中发挥重要作用。本研究旨在评估肿瘤抑素-mRNA 表达与非小细胞肺癌（NSCLC）患者的临床病理特征、肿瘤血管生成和预后之间的相关性。本研究纳入了 68 例 NSCLC 患者的标本。通过定量 RT-PCR 和 ELISA 分别定量检测肿瘤组织中 tumstatin-mRNA 的表达和蛋白水平。通过 CD34 免疫染色测定微血管密度（MVD）。分析了 tumstatin-mRNA 表达水平与临床病理变量、肿瘤血管生成和预后的相关性。肿瘤组织中 tumstatin-mRNA 表达水平降低。Tumstatin-mRNA 表达水平与肿瘤组织中的蛋白水平显著相关（r = 0.562；P = 0.001）。低分化肿瘤组织中的 tumstatin-mRNA 表达水平明显低于高分化肿瘤组织（P < 0.004）。此外，肿瘤 tumstatin-mRNA 表达也与肿瘤病理分期（P = 0.032）和 MVD（r = -0.77，P < 0.0001）显著相关。总生存（OS）和无病生存（DFS）分析表明，Tumstatin-mRNA 低表达的 NSCLC 患者的 OS 和 DFS 明显低于高表达患者（P = 0.015 和 0.037；分别）。多变量 Cox 回归分析显示，Tumstatin-mRNA 表达可作为 DFS 和 OS 的独立预后指标。Tumstatin-mRNA 表达水平在 NSCLC 组织中下调。Tumstatin-mRNA 表达水平与预后相关，提示 Tumstatin-mRNA 是 NSCLC 中一种新的潜在独立预后良好的标志物。
